Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved ...
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance ...
Once-weekly subcutaneous initiation dosing offers an at-home alternative for adults with MCI or mild dementia due to Alzheimer’s disease, potentially reducing infusion-center dependence and visit ...
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose ...
Joseph Mikhael, MD, MEd, highlights the clinical and logistical advantages of the novel on-body injector developed for the ...
Joseph Mikhael, MD, MEd, discusses the potential and limitations of at-home cancer care using on-body injection technology.
Eisai and Biogen have announced that the U.S. Food and Drug Administration has approved a supplemental biologics licence application for a once weekly subcutaneous initiation dose ...
Agreement provides Incyte the rights to develop and commercialize ENHANZE® with its mutCALR development program and an option to nominate up to two additional targets ...
Temporary Suspension of KOSPI Transfer Listing...Background of Staying Attracts Attention While Alteogen has faced share ...
A real world study suggests found that more than three-quarters of participants receiving the anti-amyloid drug Leqembi ...
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer’s Association International Conference ® (AAIC ®) 2026 in London support that the LEQEMBI ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results